RGEN (Repligen) Payments of Debt: $0.0 Mil (TTM As of Mar. 2026)


RGEN Repligen Corp RGEN
84 GF Score
Price $139.40
GF Value $176.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Payments of Debt?

Repligen RGEN -1.45% 84 Payments of Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Repligen's Payments of Debt for the three months ended in Mar. 2026 was $0.0 Mil.

Repligen's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Repligen Payments of Debt Related Terms

Repligen Payments of Debt Historical Data

* Premium members only.

The historical data trend for Repligen's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Payments of Debt Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.00 0.00 -69.94 0.00

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RGEN
84GF Score
Repligen Corp RGEN
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.0 Mil mean?
Repligen (RGEN) has a Payments of Debt of $0.0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Repligen and its competitors.
Is Repligen's Payments of Debt too high?
Repligen's current Payments of Debt is $0.0 Mil. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Payments of Debt compare to ATR and AVTR?
Repligen's Payments of Debt of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Repligen and its competitors. Repligen's current Payments of Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.53, compared to a current price of $139.40 — trading 21% below its estimated fair value. The current Payments of Debt is $0.0 Mil. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Repligen (RGEN), the current Payments of Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $139.40 is trading 21% below its estimated GF Value™ of $176.53. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Payments of Debt: $0.0 Mil
  • GF Value™: $176.53 vs. price of $139.40 (21% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$139.40
Price
$176.53
GF Value